{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:44:21Z","timestamp":1793825061170,"version":"4.6.1"},"reference-count":97,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fondazione Italo Monzino, Milan, Italy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common form of dementia in the elderly. Together with cerebral amyloid accumulation, several factors contribute to AD pathology including vascular alterations, systemic inflammation, genetic\/epigenetic status and mitochondrial dysfunction. Much is now being devoted to neuroinflammation. However, anti-inflammatory drugs as numerous other therapies, mainly targeted on \u03b2-amyloid, have failed to show efficacious effects in AD. Timing, proper selection of patients, and the need for a multitarget approach appear to be the main weak points of current therapeutic efforts. The efficacy of a treatment could be better evaluate if efficient biomarkers are available. We propose here the application of precision medicine principles in AD to simultaneously verify the efficacy of a treatment and the reliability of specific biomarkers according to individually tailored biomarker-guided targeted therapies. People at risk of developing AD or in the very early phase of the disease should be stratified according to: (1) neuropsychological tests; (2) apolipoprotein E (ApoE) genotyping; (3) biochemical analysis of plasma and cerebrospinal fluid (CSF); (4) MRI and positron emission tomography and (5) assessment of their inflammatory profile by an integration of various genetic and biochemical parameters in plasma, CSF and an analysis of microbiota composition. The selected population should be treated with antiamyloidogenic and anti-inflammatory drugs in randomised, longitudinal, placebo-controlled studies using ad hoc profiles (eg, vascular profile, mitochondrial profile, etc\u2026) If these criteria are adopted widely and the results shared, it may be possible to rapidly develop innovative and personalised drug treatment protocols with more realistic chances of being efficacious.<\/jats:p>","DOI":"10.1136\/bmjno-2020-000079","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T16:00:14Z","timestamp":1605196814000},"page":"e000079","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Alzheimer\u2019s disease: from basic science to precision medicine approach"],"prefix":"10.1136","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-3914","authenticated-orcid":false,"given":"Gianluigi","family":"Forloni","sequence":"first","affiliation":[{"name":"Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"2025072811385123000_2.2.e000079.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30299-5"},{"key":"2025072811385123000_2.2.e000079.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270502"},{"key":"2025072811385123000_2.2.e000079.3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-014-0295-9"},{"key":"2025072811385123000_2.2.e000079.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-010-8141-7"},{"key":"2025072811385123000_2.2.e000079.5","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"2025072811385123000_2.2.e000079.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"2025072811385123000_2.2.e000079.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30480-6"},{"key":"2025072811385123000_2.2.e000079.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0127-z"},{"key":"2025072811385123000_2.2.e000079.9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer's disease","volume":"6","author":"Neddens","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"2025072811385123000_2.2.e000079.10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12149-020-01506-2","article-title":"Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study","volume":"34","author":"Xu","year":"2020","journal-title":"Ann Nucl Med"},{"key":"2025072811385123000_2.2.e000079.11","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","article-title":"18F-MK-6240 PET for early and late detection of neurofibrillary tangles","volume":"143","author":"Pascoal","year":"2020","journal-title":"Brain"},{"key":"2025072811385123000_2.2.e000079.12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2025072811385123000_2.2.e000079.13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2025072811385123000_2.2.e000079.14","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060667","article-title":"Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression","volume":"11","author":"Chakravarthy","year":"2020","journal-title":"Genes"},{"key":"2025072811385123000_2.2.e000079.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0238-6"},{"key":"2025072811385123000_2.2.e000079.16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2017.08.028","article-title":"Exosomal biomarkers in Down syndrome and Alzheimer's disease","volume":"114","author":"Hamlett","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"2025072811385123000_2.2.e000079.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-019-0317-5","article-title":"Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimer's disease","volume":"14","author":"Watson","year":"2019","journal-title":"Mol Neurodegener"},{"key":"2025072811385123000_2.2.e000079.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316551"},{"key":"2025072811385123000_2.2.e000079.19","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00015","article-title":"The contribution of iron to protein aggregation disorders in the central nervous system","volume":"13","author":"Joppe","year":"2019","journal-title":"Front Neurosci"},{"key":"2025072811385123000_2.2.e000079.20","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.21730"},{"key":"2025072811385123000_2.2.e000079.21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00165","article-title":"Hfe gene variants, iron, and lipids: a novel connection in Alzheimer's disease","volume":"5","author":"Ali-Rahmani","year":"2014","journal-title":"Front Pharmacol"},{"key":"2025072811385123000_2.2.e000079.22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/ph11040109","article-title":"New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases","volume":"11","author":"Nu\u00f1ez","year":"2018","journal-title":"Pharmaceuticals"},{"key":"2025072811385123000_2.2.e000079.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2019.12.011","article-title":"Molecular targets and therapeutic interventions for iron induced neurodegeneration","volume":"156","author":"Bagwe-Parab","year":"2020","journal-title":"Brain Res Bull"},{"key":"2025072811385123000_2.2.e000079.24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","article-title":"Biological subtypes of Alzheimer disease: a systematic review and meta-analysis","volume":"94","author":"Ferreira","year":"2020","journal-title":"Neurology"},{"key":"2025072811385123000_2.2.e000079.25","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.3784","article-title":"Pragmatic trials and repurposed drugs for Alzheimer disease","volume":"77","author":"Schneider","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025072811385123000_2.2.e000079.26","unstructured":"EMA, Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. Available: https:\/\/www.ema.europa. eu\/en\/clinical-investigation-medicines-treatment-alzheimers-disease"},{"key":"2025072811385123000_2.2.e000079.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"},{"key":"2025072811385123000_2.2.e000079.28","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(89)90169-9"},{"key":"2025072811385123000_2.2.e000079.29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neurobiolaging.2017.03.005","article-title":"Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan","volume":"54","author":"LeVine","year":"2017","journal-title":"Neurobiol Aging"},{"key":"2025072811385123000_2.2.e000079.30","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000171397.32851.bc"},{"key":"2025072811385123000_2.2.e000079.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00135-0"},{"key":"2025072811385123000_2.2.e000079.32","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23650"},{"key":"2025072811385123000_2.2.e000079.33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002923"},{"key":"2025072811385123000_2.2.e000079.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2025072811385123000_2.2.e000079.35","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2214","article-title":"Staging \u03b2 -Amyloid Pathology With Amyloid Positron Emission Tomography","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025072811385123000_2.2.e000079.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.7437"},{"key":"2025072811385123000_2.2.e000079.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0789-4"},{"key":"2025072811385123000_2.2.e000079.38","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4443"},{"key":"2025072811385123000_2.2.e000079.39","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.90"},{"key":"2025072811385123000_2.2.e000079.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001877"},{"key":"2025072811385123000_2.2.e000079.41","first-page":"652","article-title":"Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia","volume":"4","author":"Willis","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2025072811385123000_2.2.e000079.42","first-page":"402","article-title":"Phase II clinical trials of anti-amyloid \u03b2 antibodies: when is enough, enough?","volume":"3","author":"Gold","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2025072811385123000_2.2.e000079.43","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2013.00025","article-title":"Is Abeta a sufficient biomarker for monitoring anti-Abeta clinical studies? A critical review","volume":"5","author":"Moreth","year":"2013","journal-title":"Front Aging Neurosci"},{"key":"2025072811385123000_2.2.e000079.44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer's fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2025072811385123000_2.2.e000079.45","first-page":"129","article-title":"Differential effects of neurodegeneration biomarkers on subclinical cognitive decline","volume":"5","author":"Merluzzi","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2025072811385123000_2.2.e000079.46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-180261","article-title":"Urine-Based biomarkers for Alzheimer's disease identified through coupling computational and experimental methods","volume":"65","author":"Yao","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025072811385123000_2.2.e000079.47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4761054","article-title":"Biomarkers for Alzheimer's disease in saliva: a systematic review","volume":"2019","author":"Gleerup","year":"2019","journal-title":"Dis Markers"},{"key":"2025072811385123000_2.2.e000079.48","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801"},{"key":"2025072811385123000_2.2.e000079.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00070-3"},{"key":"2025072811385123000_2.2.e000079.50","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2025072811385123000_2.2.e000079.51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2025072811385123000_2.2.e000079.52","doi-asserted-by":"crossref","first-page":"10.1212\/WNL.0000000000008081","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-Precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"2025072811385123000_2.2.e000079.53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","article-title":"Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease","volume":"58","author":"Pereira","year":"2017","journal-title":"Neurobiol Aging"},{"key":"2025072811385123000_2.2.e000079.54","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861"},{"key":"2025072811385123000_2.2.e000079.55","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025072811385123000_2.2.e000079.56","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1474-4422(19)30354-0","article-title":"Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study","volume":"18","author":"van der Ende","year":"2019","journal-title":"Lancet Neurol"},{"key":"2025072811385123000_2.2.e000079.57","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awaa054","article-title":"Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study","volume":"143","author":"de Wolf","year":"2020","journal-title":"Brain"},{"key":"2025072811385123000_2.2.e000079.58","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jalz.2019.06.4952","article-title":"Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid","volume":"15","author":"Takousis","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2025072811385123000_2.2.e000079.59","doi-asserted-by":"crossref","first-page":"16122","DOI":"10.18632\/oncotarget.15109","article-title":"Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects","volume":"8","author":"Nagaraj","year":"2017","journal-title":"Oncotarget"},{"key":"2025072811385123000_2.2.e000079.60","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00278","article-title":"Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes","volume":"11","author":"Mustapic","year":"2017","journal-title":"Front Neurosci"},{"key":"2025072811385123000_2.2.e000079.61","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.12659\/MSM.914027","article-title":"Exosomes in pathogenesis, diagnosis, and treatment of Alzheimer's disease","volume":"25","author":"Jiang","year":"2019","journal-title":"Med Sci Monit"},{"key":"2025072811385123000_2.2.e000079.62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00310","article-title":"Biomarker-Drug and liquid biopsy Co-development for disease staging and targeted therapy: Cornerstones for Alzheimer's precision medicine and pharmacology","volume":"10","author":"Hampel","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025072811385123000_2.2.e000079.63","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/bmm-2017-0388","article-title":"A review of biomarkers of Alzheimer's disease in noninvasive samples","volume":"12","author":"Hartmann","year":"2018","journal-title":"Biomark Med"},{"key":"2025072811385123000_2.2.e000079.64","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0242-x"},{"key":"2025072811385123000_2.2.e000079.65","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.26624","article-title":"Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases","volume":"31","author":"Forloni","year":"2016","journal-title":"Mov Disord"},{"key":"2025072811385123000_2.2.e000079.66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbi.2018.02.012","article-title":"Alpha-Synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2","volume":"69","author":"La Vitola","year":"2018","journal-title":"Brain Behav Immun"},{"key":"2025072811385123000_2.2.e000079.67","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/gps.5124","article-title":"Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease","volume":"34","author":"King","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025072811385123000_2.2.e000079.68","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.2.447"},{"key":"2025072811385123000_2.2.e000079.69","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"2025072811385123000_2.2.e000079.70","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-170819","article-title":"Alzheimer's disease, oligomers, and inflammation","volume":"62","author":"Forloni","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025072811385123000_2.2.e000079.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010178"},{"key":"2025072811385123000_2.2.e000079.72","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)90598-3"},{"key":"2025072811385123000_2.2.e000079.73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05623-9"},{"key":"2025072811385123000_2.2.e000079.74","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4142"},{"key":"2025072811385123000_2.2.e000079.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2013.07.002"},{"key":"2025072811385123000_2.2.e000079.76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neurobiolaging.2018.06.002","article-title":"Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models","volume":"70","author":"Balducci","year":"2018","journal-title":"Neurobiol Aging"},{"key":"2025072811385123000_2.2.e000079.77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911829107"},{"key":"2025072811385123000_2.2.e000079.78","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1954"},{"key":"2025072811385123000_2.2.e000079.79","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/CIA.S169565","article-title":"Physical activity can improve cognition in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Du","year":"2018","journal-title":"Clin Interv Aging"},{"key":"2025072811385123000_2.2.e000079.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.10.009"},{"key":"2025072811385123000_2.2.e000079.81","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000496"},{"key":"2025072811385123000_2.2.e000079.82","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","article-title":"Csf biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease","volume":"91","author":"Janelidze","year":"2018","journal-title":"Neurology"},{"key":"2025072811385123000_2.2.e000079.83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050993","article-title":"Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging","volume":"18","author":"Cerami","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025072811385123000_2.2.e000079.84","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14789450.2019.1628643","article-title":"The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development","volume":"16","author":"Baldacci","year":"2019","journal-title":"Expert Rev Proteomics"},{"key":"2025072811385123000_2.2.e000079.85","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/13892037113149990144","article-title":"CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study","volume":"10","author":"Ross","year":"2013","journal-title":"Curr Alzheimer Res"},{"key":"2025072811385123000_2.2.e000079.86","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12522"},{"key":"2025072811385123000_2.2.e000079.87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-181121","article-title":"The Alzheimer precision medicine initiative","volume":"68","author":"Hampel","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2025072811385123000_2.2.e000079.88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21037\/atm.2016.03.05","article-title":"Toward precision medicine in Alzheimer's disease","volume":"4","author":"Reitz","year":"2016","journal-title":"Ann Transl Med"},{"key":"2025072811385123000_2.2.e000079.89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13697137.2017.1287866","article-title":"A precision medicine initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling","volume":"20","author":"Hampel","year":"2017","journal-title":"Climacteric"},{"key":"2025072811385123000_2.2.e000079.90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000354228","article-title":"Neuroinflammatory phenotypes and their roles in Alzheimer's disease","volume":"13","author":"Wilcock","year":"2014","journal-title":"Neurodegener Dis"},{"key":"2025072811385123000_2.2.e000079.91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/JAD-160889","article-title":"The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in\u00a0Alzheimer's Disease","volume":"56","author":"Morgan","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2025072811385123000_2.2.e000079.92","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jalz.2019.03.007","article-title":"Inflammatory biomarkers in Alzheimer's disease plasma","volume":"15","author":"Morgan","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2025072811385123000_2.2.e000079.93","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316201"},{"key":"2025072811385123000_2.2.e000079.94","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1399-2"},{"key":"2025072811385123000_2.2.e000079.95","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)02380-2"},{"key":"2025072811385123000_2.2.e000079.96","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12640-015-9592-2","article-title":"Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways","volume":"29","author":"Santa-Cec\u00edlia","year":"2016","journal-title":"Neurotox Res"},{"key":"2025072811385123000_2.2.e000079.97","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/bs.irn.2019.03.001","article-title":"Dysfunction of mitochondria: implications for Alzheimer's disease","volume":"145","author":"Albensi","year":"2019","journal-title":"Int Rev Neurobiol"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2020-000079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:39:05Z","timestamp":1753727945000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2020-000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":97,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,12]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjno-2020-000079"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2020-000079","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}